Marker Therapeutics Stock Price

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Marker Therapeutics Inc MRKR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.71 20:00:00
Close Price Low Price High Price Open Price Previous Close
1.7117 1.66 1.75 1.75 1.71
Bid Price Ask Price Spread News
1.59 1.74 0.15 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
960 183,290 $ 1.73 $ 316,295 235,325 1.33 - 6.22
Last Trade Time Type Quantity Stock Price Currency
17:24:49 formt 1,062 $ 1.71 USD

Marker Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 79.72M 46.62M 27.26M $ 213.19k $ - -0.47 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Marker Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MRKR Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.551.751.461.60256,7920.1610.32%
1 Month1.881.941.4361.64225,943-0.17-9.04%
3 Months2.022.231.4361.88251,669-0.31-15.35%
6 Months1.943.221.4362.15381,433-0.23-11.86%
1 Year6.086.221.332.61349,300-4.37-71.88%
3 Years10.0110.251.334.50374,304-8.30-82.92%
5 Years10.0110.251.334.50374,304-8.30-82.92%

Marker Therapeutics Description

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Your Recent History
Marker The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.